Trimeris has appointed Martin A. Mattingly, Pharm.D. as chief executive officer. Dr. Mattingly will also join the Company’s board of directors. Julian Baker, a member of the company’s board of directors, remarked, “The Trimeris Board is extremely excited by Martin’s decision to join the Company. His hands-on experience in commercializing HIV products in crowded markets and in maximizing the value of these products as they mature is an ideal fit for Trimeris. During his...